Cyrenaic Pharmaceuticals Inc. (“Cyrenaic”), a private drug development company focused on the treatment of CNS disorders, today announced Phase IIa clinical results for CYR-101, its novel investigational drug for the treatment of schizophrenia. The results from the study showed that the drug alleviated the symptoms of the disease, including the negative and cognitive symptoms.
Cyrenaic Pharmaceuticals Reports Improvement of Negative Symptoms and Cognition in Schizophrenia Patients Treated with CYR-101
Комментариев нет:
Отправить комментарий